Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
TR2-H5257 | Human | Human TREM2 (19-131) Protein, Fc Tag |
|
||
TR2-H5254 | Human | Human TREM2 Protein, Fc Tag |
|
||
TR2-C52H3 | Cynomolgus | Cynomolgus TREM2 Protein, His Tag |
|
||
TR2-M5254 | Mouse | Mouse TREM2 Protein, Fc Tag |
|
||
TR2-H5256 | Human | Human TREM2 Protein, Mouse IgG2a Fc Tag |
|
||
TR2-M52H3 | Mouse | Mouse TREM2 Protein, His Tag |
|
||
TR2-H52H5 | Human | Human TREM2 Protein, His Tag |
|
||
TR2-H82E7 | Human | Biotinylated Human TREM2 Protein, His,Avitag™ |
|
Anti-TREM2 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TREM2, His Tag (Cat. No. TR2-H52H5) with an affinity constant of 95.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AL-002 | AL-002a; AL-002-a; AL-002 | Phase 2 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
Iluzanebart | VGL-101; VGL 101 | Phase 2 Clinical | Amgen Inc | Posterior Leukoencephalopathy Syndrome; Nerve Degeneration | Details |
DNL-919 | DNL-919; TAK-920 | Phase 1 Clinical | Denali Therapeutics Inc | Alzheimer Disease | Details |
VG-3927 | VG-3927 | Phase 1 Clinical | Vigil Neuroscience Inc | Alzheimer Disease | Details |
AL-002 | AL-002a; AL-002-a; AL-002 | Phase 2 Clinical | Abbvie Inc, Alector Inc | Alzheimer Disease | Details |
Iluzanebart | VGL-101; VGL 101 | Phase 2 Clinical | Amgen Inc | Posterior Leukoencephalopathy Syndrome; Nerve Degeneration | Details |
DNL-919 | DNL-919; TAK-920 | Phase 1 Clinical | Denali Therapeutics Inc | Alzheimer Disease | Details |
VG-3927 | VG-3927 | Phase 1 Clinical | Vigil Neuroscience Inc | Alzheimer Disease | Details |
This web search service is supported by Google Inc.